Japan’s curbs on key semiconductor material exports to South Korea would not significantly boost the prices of memory chips in the short term, due to chipmakers’ high inventories, market researcher TrendForce Corp (集邦科技) said in a report yesterday.
Memorychip makers have seen chip prices plunging for the past three quarters due to oversupply and sluggish end product demand, TrendForce said.
The Japan-South Korea dispute led to hikes in the prices of DRAM modules, due to increasingly tight supply of key materials used in the manufacturing of semiconductors, smartphones and flat panels, the Taipei-based firm said.
However, “the possibility is slim that such disputes will trigger a short-term, structural reversal of supply and demand,” since Japan has only lengthened the export procedures for photoresist, hydrogen fluoride and etching gas to South Korea, but did not ban them altogether, the report said.
High inventories could serve as a buffer, TrendForce implied.
As DRAM suppliers generally have more than three months of chips in stock, prices for DRAM chips used in PCs, servers and handsets are likely to see an extended decline at the beginning of this quarter, TrendForce said.
“No signs of reversal are found as of present,” it said. “The possibility of a structural reversal of supply and demand in the DRAM market should be slim.”
On the NAND flash front, prices are to increase this month, as supply tightened amid Japan’s export controls and Toshiba Memory Corp’s production loss from a brief power outage last month, the report said.
However, the price increases would be short-lived, given that NAND flash chip suppliers usually keep two to three months of chips in their inventories, the report said.
In the long run, NAND flash memorychip makers face downward price pressure, TrendForce said.
JPMorgan Chase & Co chief executive officer Jamie Dimon on Tuesday quipped that his company is likely to outlast the Chinese Communist Party (CCP), while reiterating the bank’s commitment to the country in wide-ranging comments that also touched on Taiwan, free speech and former US president Donald Trump. “We hope to be there [in China] for a long time,” Dimon told a panel discussion at the Boston College Chief Executives Club. Relaying a “joke” he made during a recent visit to Hong Kong, he said “The communist party is celebrating its 100th year. So is JPMorgan. And I’ll make you a
The Kaohsiung City Government yesterday said it would impose a property hoarding tax as it is seeking to contain speculation in the real-estate market, calling recent price increases “abnormal.” The announcement came in support of the Ministry of Finance’s call for local governments to levy a high tax rate on people with more than one property. Ministry officials on Tuesday discussed strategies to rein in speculation with the nation’s six special municipalities, as well as the Hsinchu city and county governments. About 84,000 out of 1.06 million housing units in Kaohsiung are not residential property, the city government said in a
BOOST EXPECTED: Higher market prices would offset effects of the industry’s transition to more climate-friendly production methods, a company official said China Steel Corp (CSC, 中鋼) expects steel demand to increase on the back of governments around the world subsidizing infrastructure construction amid a stabilizing COVID-19 pandemic, CSC chairman Wong Chao-tung (翁朝棟) told an investors’ meeting yesterday. “After getting through the hard times, I foresee at least one year, very possibly two years, of strong steel market,” Wong said. Calling a dip in steel prices a “short respite for the market,” Wong said that it would likely bounce back early next year on the back of mild winter temperatures around the world allowing construction activity. Despite COVID-19 spikes in some regions and increased
PharmaEssentia Corp (藥華醫藥) shares have jumped 80.56 percent since the company obtained a US polycythemia vera (PV) drug license for its new interferon drug Besremi (ropeginterferon alfa-2b-njft) on Nov. 12. Shares on Friday closed at NT$195 in Taipei trading, up from the stock’s closing price of NT$108 on Nov. 12. PV is a rare, chronic and life-threatening blood cancer linked to a stem cell mutation in the bone marrow that results in an overproduction of blood cells and places sufferers at risk of having a blood clot, stroke or heart attack. PharmaEssentia is preparing to make Besremi available in the US in the